EMUC15 - Resource Centre - Search Results

178 results (Loading...)

Video Filters×
  • organe

  • access

  • procedure

  • pathology

178 Abstracts

  • Introduction & ObjectivesTo determine the efficacy of combined androgen block (CAB) vs. GnRH agonist monotherapy in terms of bone mineral density (BMD) change during 12 months post-treatment initiation in prostate cancer patients.Material & MethodsThis was a multi-center, prospective observational study on patients who were scheduled to receive continuous androgen deprivation therapy (ADT) with CAB (CAB group) or GnRH agonist monotherapy (GnRH group). BMD was measured from baseline to 12 month post-ADT initiation by dual energy x-ray absorptiometry. We also investigated the underlying factors affecting BMD and estimated the 10-year probability of major fractures among the patients with Fracture Risk Assessment Tool.ResultsBMD significantly decreased in the CAB and GnRH groups, with no group wise differences. However, the non-inferiority of the CAB group was not determined with statistical significance. The proportion of patients with osteopenia or osteoporosis was slightly increased after the 12th month post-ADT initiation. Ten-year probability of hip fracture and major osteoporotic fracture was approximately 3% and 5%, respectively.ConclusionsNon-inferiority of CAB therapy to GnRH monotherapy in terms of the BMD loss was not determined, but a significant decrease of BMD was observed by 12 months ADT, with no differences between the 2 groups. BMD loss induced by 12 months ADT did not induce detrimental effects on bone health in terms of increased bone fracture risk. This was the first prospective study on BMD changes as a predictor of fracture during ADT in an Asian population. Joung J.Y.1, Rha K.H.2, Kim H.G.3, Kwak C.4, Lee J.Y.5, Jeon S.S.6, Hong S.K.4, Jeong H.7, Jo M.K.8, Jeong I.G.9, Hong J.H.9, Kim C.9 7th European Multidisciplinary Meeting on Urological Cancers 1National Cancer Center, Dept. of Urology & Oncology, Goyang, 2Severance Hospital, Dept. of Urology, Seoul, 3Konkuk University, Dept. of Urology, Seoul, 4Seoul National University, Dept. of Urology, Seoul, 5The Catholic Unveristy, Dept. of Urology, Seoul, 6Samsung Medical Center, Dept. of Urology, Seoul, 7Boramae Medical Center, Dept. of Urology, Seoul, 8Korea Cancer Hospital, Dept. of Urology, Seoul, 9Asan Medical Center, Dept. of Urology, Seoul 58521 EMUC15-0049 P070
  • Introduction & ObjectivesTo determine the efficacy of combined androgen block (CAB) vs. GnRH agonist monotherapy in terms of bone mineral density (BMD) change during 12 months post-treatment initiation in prostate cancer patients.Material & MethodsThis was a multi-center, prospective observational study on patients who were scheduled to receive continuous androgen deprivation therapy (ADT) with CAB (CAB group) or GnRH agonist monotherapy (GnRH group). BMD was measured from baseline to 12 month post-ADT initiation by dual energy x-ray absorptiometry. We also investigated the underlying factors affecting BMD and estimated the 10-year probability of major fractures among the patients with Fracture Risk Assessment Tool.ResultsBMD significantly decreased in the CAB and GnRH groups, with no group wise differences. However, the non-inferiority of the CAB group was not determined with statistical significance. The proportion of patients with osteopenia or osteoporosis was slightly increased after the 12th month post-ADT initiation. Ten-year probability of hip fracture and major osteoporotic fracture was approximately 3% and 5%, respectively.ConclusionsNon-inferiority of CAB therapy to GnRH monotherapy in terms of the BMD loss was not determined, but a significant decrease of BMD was observed by 12 months ADT, with no differences between the 2 groups. BMD loss induced by 12 months ADT did not induce detrimental effects on bone health in terms of increased bone fracture risk. This was the first prospective study on BMD changes as a predictor of fracture during ADT in an Asian population. Joung J.Y.1, Rha K.H.2, Kim H.G.3, Kwak C.4, Lee J.Y.5, Jeon S.S.6, Hong S.K.4, Jeong H.7, Jo M.K.8, Jeong I.G.9, Hong J.H.9, Kim C.9 7th European Multidisciplinary Meeting on Urological Cancers 1National Cancer Center, Dept. of Urology & Oncology, Goyang, 2Severance Hospital, Dept. of Urology, Seoul, 3Konkuk University, Dept. of Urology, Seoul, 4Seoul National University, Dept. of Urology, Seoul, 5The Catholic Unveristy, Dept. of Urology, Seoul, 6Samsung Medical Center, Dept. of Urology, Seoul, 7Boramae Medical Center, Dept. of Urology, Seoul, 8Korea Cancer Hospital, Dept. of Urology, Seoul, 9Asan Medical Center, Dept. of Urology, Seoul 58521 EMUC15-0049 P070
  • Introduction & ObjectivesTo determine the efficacy of combined androgen block (CAB) vs. GnRH agonist monotherapy in terms of bone mineral density (BMD) change during 12 months post-treatment initiation in prostate cancer patients.Material & MethodsThis was a multi-center, prospective observational study on patients who were scheduled to receive continuous androgen deprivation therapy (ADT) with CAB (CAB group) or GnRH agonist monotherapy (GnRH group). BMD was measured from baseline to 12 month post-ADT initiation by dual energy x-ray absorptiometry. We also investigated the underlying factors affecting BMD and estimated the 10-year probability of major fractures among the patients with Fracture Risk Assessment Tool.ResultsBMD significantly decreased in the CAB and GnRH groups, with no group wise differences. However, the non-inferiority of the CAB group was not determined with statistical significance. The proportion of patients with osteopenia or osteoporosis was slightly increased after the 12th month post-ADT initiation. Ten-year probability of hip fracture and major osteoporotic fracture was approximately 3% and 5%, respectively.ConclusionsNon-inferiority of CAB therapy to GnRH monotherapy in terms of the BMD loss was not determined, but a significant decrease of BMD was observed by 12 months ADT, with no differences between the 2 groups. BMD loss induced by 12 months ADT did not induce detrimental effects on bone health in terms of increased bone fracture risk. This was the first prospective study on BMD changes as a predictor of fracture during ADT in an Asian population. Joung J.Y.1, Rha K.H.2, Kim H.G.3, Kwak C.4, Lee J.Y.5, Jeon S.S.6, Hong S.K.4, Jeong H.7, Jo M.K.8, Jeong I.G.9, Hong J.H.9, Kim C.9 7th European Multidisciplinary Meeting on Urological Cancers 1National Cancer Center, Dept. of Urology & Oncology, Goyang, 2Severance Hospital, Dept. of Urology, Seoul, 3Konkuk University, Dept. of Urology, Seoul, 4Seoul National University, Dept. of Urology, Seoul, 5The Catholic Unveristy, Dept. of Urology, Seoul, 6Samsung Medical Center, Dept. of Urology, Seoul, 7Boramae Medical Center, Dept. of Urology, Seoul, 8Korea Cancer Hospital, Dept. of Urology, Seoul, 9Asan Medical Center, Dept. of Urology, Seoul 58521 EMUC15-0049 P070
  • Introduction & ObjectivesTo determine the efficacy of combined androgen block (CAB) vs. GnRH agonist monotherapy in terms of bone mineral density (BMD) change during 12 months post-treatment initiation in prostate cancer patients.Material & MethodsThis was a multi-center, prospective observational study on patients who were scheduled to receive continuous androgen deprivation therapy (ADT) with CAB (CAB group) or GnRH agonist monotherapy (GnRH group). BMD was measured from baseline to 12 month post-ADT initiation by dual energy x-ray absorptiometry. We also investigated the underlying factors affecting BMD and estimated the 10-year probability of major fractures among the patients with Fracture Risk Assessment Tool.ResultsBMD significantly decreased in the CAB and GnRH groups, with no group wise differences. However, the non-inferiority of the CAB group was not determined with statistical significance. The proportion of patients with osteopenia or osteoporosis was slightly increased after the 12th month post-ADT initiation. Ten-year probability of hip fracture and major osteoporotic fracture was approximately 3% and 5%, respectively.ConclusionsNon-inferiority of CAB therapy to GnRH monotherapy in terms of the BMD loss was not determined, but a significant decrease of BMD was observed by 12 months ADT, with no differences between the 2 groups. BMD loss induced by 12 months ADT did not induce detrimental effects on bone health in terms of increased bone fracture risk. This was the first prospective study on BMD changes as a predictor of fracture during ADT in an Asian population. Joung J.Y.1, Rha K.H.2, Kim H.G.3, Kwak C.4, Lee J.Y.5, Jeon S.S.6, Hong S.K.4, Jeong H.7, Jo M.K.8, Jeong I.G.9, Hong J.H.9, Kim C.9 7th European Multidisciplinary Meeting on Urological Cancers 1National Cancer Center, Dept. of Urology & Oncology, Goyang, 2Severance Hospital, Dept. of Urology, Seoul, 3Konkuk University, Dept. of Urology, Seoul, 4Seoul National University, Dept. of Urology, Seoul, 5The Catholic Unveristy, Dept. of Urology, Seoul, 6Samsung Medical Center, Dept. of Urology, Seoul, 7Boramae Medical Center, Dept. of Urology, Seoul, 8Korea Cancer Hospital, Dept. of Urology, Seoul, 9Asan Medical Center, Dept. of Urology, Seoul 58521 EMUC15-0049 P070
  • Introduction & ObjectivesTo determine the efficacy of combined androgen block (CAB) vs. GnRH agonist monotherapy in terms of bone mineral density (BMD) change during 12 months post-treatment initiation in prostate cancer patients.Material & MethodsThis was a multi-center, prospective observational study on patients who were scheduled to receive continuous androgen deprivation therapy (ADT) with CAB (CAB group) or GnRH agonist monotherapy (GnRH group). BMD was measured from baseline to 12 month post-ADT initiation by dual energy x-ray absorptiometry. We also investigated the underlying factors affecting BMD and estimated the 10-year probability of major fractures among the patients with Fracture Risk Assessment Tool.ResultsBMD significantly decreased in the CAB and GnRH groups, with no group wise differences. However, the non-inferiority of the CAB group was not determined with statistical significance. The proportion of patients with osteopenia or osteoporosis was slightly increased after the 12th month post-ADT initiation. Ten-year probability of hip fracture and major osteoporotic fracture was approximately 3% and 5%, respectively.ConclusionsNon-inferiority of CAB therapy to GnRH monotherapy in terms of the BMD loss was not determined, but a significant decrease of BMD was observed by 12 months ADT, with no differences between the 2 groups. BMD loss induced by 12 months ADT did not induce detrimental effects on bone health in terms of increased bone fracture risk. This was the first prospective study on BMD changes as a predictor of fracture during ADT in an Asian population. Joung J.Y.1, Rha K.H.2, Kim H.G.3, Kwak C.4, Lee J.Y.5, Jeon S.S.6, Hong S.K.4, Jeong H.7, Jo M.K.8, Jeong I.G.9, Hong J.H.9, Kim C.9 7th European Multidisciplinary Meeting on Urological Cancers 1National Cancer Center, Dept. of Urology & Oncology, Goyang, 2Severance Hospital, Dept. of Urology, Seoul, 3Konkuk University, Dept. of Urology, Seoul, 4Seoul National University, Dept. of Urology, Seoul, 5The Catholic Unveristy, Dept. of Urology, Seoul, 6Samsung Medical Center, Dept. of Urology, Seoul, 7Boramae Medical Center, Dept. of Urology, Seoul, 8Korea Cancer Hospital, Dept. of Urology, Seoul, 9Asan Medical Center, Dept. of Urology, Seoul 58521 EMUC15-0049 P070
×